EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)

Adarsh Bhimraj, Rebecca L Morgan, Amy Hirsch Shumaker, Lindsey R Baden, Vincent Chi-Chung Cheng, Kathryn M Edwards, Jason C Gallagher, Rajesh T Gandhi, William J Muller, Mari M Nakamura, John C O'Horo, Robert W Shafer und 5 weitere

Clinical Infectious Diseases · 27.06.2024 · 78 (7) · e250-e349

DOI: 10.1093/cid/ciac724 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.09.2022. Verfasst von Adarsh Bhimraj und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 196-mal zitiert (Crossref) und nennt 361 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, CDC HHS, HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials. The objective was to develop evidence-based, rapid, living guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. In March 2020, the Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise to regularly review the evidence and make recommendations about the treatment and management of persons with COVID-19. The process used a living guideline approach and followed a rapid recommendation development checklist. The panel prioritized questions and outcomes. A systematic review of the peer-reviewed and grey literature was conducted at regular intervals. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Based on the most recent search conducted on 31 May 2022, the IDSA guideline panel has made 32 recommendations for the treatment and management of the following groups/populations: pre- and postexposure prophylaxis, ambulatory with mild-to-moderate disease, and hospitalized with mild-to-moderate, severe but not critical, and critical disease. As these are living guidelines, the most recent recommendations can be found online at: https://idsociety.org/COVID19guidelines. At the inception of its work, the panel has expressed the overarching goal that patients be recruited into ongoing trials. Since then, many trials were conducted that provided much-needed evidence for COVID-19 therapies. There still remain many unanswered questions as the pandemic evolved, which we hope future trials can answer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2HumansUnited StatesAntiviral AgentsCOVID-19 Drug Treatment

Stichwörter der Autor:innen

2019-nCoVCOVID-19SARS-Cov-2antiviralscorona virus

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
  • VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
  • Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Queen Mary Hospital, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

Förderung

  • NIAID NIH HHS
  • CDC HHS
  • HHS
  • Centers for Disease Control and Prevention
  • Department of Health and Human Services

Zitieren

APA

Bhimraj, A., Morgan, R. L., Shumaker, A. H., Baden, L. R., Cheng, V. C., Edwards, K. M., Gallagher, J. C., Gandhi, R. T., Muller, W. J., Nakamura, M. M., O'Horo, J. C., Shafer, R. W., Shoham, S., Murad, M. H., Mustafa, R. A., Sultan, S., & Falck-Ytter, Y. (2024). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022). Clinical Infectious Diseases, 78(7), e250-e349. https://doi.org/10.1093/cid/ciac724

Vancouver

Bhimraj A, Morgan RL, Shumaker AH, Baden LR, Cheng VC, Edwards KM, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022). Clinical Infectious Diseases. 2024;78(7):e250-e349. doi:10.1093/cid/ciac724

BibTeX
@article{Bhimraj2024,
  author = {Bhimraj, Adarsh and Morgan, Rebecca L and Shumaker, Amy Hirsch and Baden, Lindsey R and Cheng, Vincent Chi-Chung and Edwards, Kathryn M and Gallagher, Jason C and Gandhi, Rajesh T and Muller, William J and Nakamura, Mari M and O'Horo, John C and Shafer, Robert W and Shoham, Shmuel and Murad, M Hassan and Mustafa, Reem A and Sultan, Shahnaz and Falck-Ytter, Yngve},
  title = {Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {7},
  pages = {e250--e349},
  doi = {10.1093/cid/ciac724}
}
Kostenlos starten →